Last reviewed · How we verify
Furosemide intravenous infusion
Furosemide inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, promoting diuresis and reducing fluid overload.
Furosemide inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, promoting diuresis and reducing fluid overload. Used for Acute decompensated heart failure with fluid overload, Pulmonary edema, Edema associated with renal disease or hepatic cirrhosis.
At a glance
| Generic name | Furosemide intravenous infusion |
|---|---|
| Sponsor | Wroclaw Medical University |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This increases urine output and reduces circulating fluid volume, thereby decreasing cardiac preload and pulmonary/peripheral edema. The intravenous formulation provides rapid onset of action suitable for acute decompensated heart failure and other conditions requiring urgent diuresis.
Approved indications
- Acute decompensated heart failure with fluid overload
- Pulmonary edema
- Edema associated with renal disease or hepatic cirrhosis
- Hypertension
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (high-dose IV)
- Hypotension
- Hyperglycemia
- Dehydration
- Electrolyte imbalances
Key clinical trials
- Comparison of the Effectiveness of Different Diuretic Therapies in the Management of Acute Heart Failure (NA)
- Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group (NA)
- A Study of Ultra High Dose Diuretics to Treat Heart Failure (PHASE2)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (PHASE1, PHASE2)
- Loop Diuretic Therapy in Acutely Decompensated Heart Failure
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants (PHASE1)
- The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |